A study has shown that, for people living with advanced cancer, a simple, weekly remote check-in with their care team can ...

AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5 billion agreement that gives it global rights ...

After a delay, Eisai and Biogen have won FDA approval for their new subcutaneous formulation of Alzheimer's disease therapy ...

As the hype builds around radiopharmaceuticals, Novartis’s Pluvicto (lutetium PSA) remains one of the few that’s actually made it to market. In a conversation at ASCO 2026, Dr Fred Saad of the ...

Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade, particularly for patients whose tumours harbour mutations in the epidermal ...

GSK's pivotal AZUR-1 trial of cancer immunotherapy Jemperli, as a way to delay or eliminate surgery in pre-operative rectal ...

Apnimed has joined the IPO queue on the Nasdaq, hoping to raise additional funding for its late-stage oral therapy for ...

A large-scale trial has been launched, with $100 million in backing, to explore whether lifestyle changes coupled with GLP-1 ...

EU pharmaceutical safety advisers have said that commonly used contraceptives may carry a small risk of a type of brain ...

Organisations are beginning to rethink field integration more holistically out of a realisation that consistency in ...

Hundreds of researchers at the Institute of Cancer Research (ICR) in London have held historic strikes across sites in Sutton ...

Vertex Pharma has made the largest acquisition in its history, agreeing to buy Crinetics Pharma for around $10 billion in a ...